Is there a place for drug combination strategies using clinical pharmacology attributes? - Review of current trends in research

Current Clinical Pharmacology

Volumn 4, Issue 3, 2009, Pages 220-228

  Srinivas, Nuggehally R ^a  

^a Integrated Drug Development   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIDEPRESSANT AGENT; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DOCETAXEL; DRUG METABOLITE; KETOCONAZOLE; LANIQUIDAR; NELFINAVIR; NELFINAVIR HYDROXYL TERT BUTYLAMIDE; ORGANIC ANION TRANSPORTER 1; OSELTAMIVIR; PROBENECID; RAVUCONAZOLE; RIFAMPICIN; RITONAVIR; UNCLASSIFIED DRUG;

ADD ON THERAPY; CASE STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MONITORING; DRUG RESEARCH; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMBINATIONS; DRUG DISCOVERY; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; MEMBRANE TRANSPORT MODULATORS; NELFINAVIR; ORGANIC ANION TRANSPORT PROTEIN 1; OSELTAMIVIR; P-GLYCOPROTEIN; PHARMACOLOGY, CLINICAL; TAXOIDS;

EID: 70549112074     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409789375285     Document Type: Review

References (52)

1. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 2008; 352: 349-356 (Pubitemid 351574780)
2. McGinnity DF, Waters NJ, Tucker J, Riley RJ. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. Drug Metab Dispos 2008; 36: 1126-1134
3. Mcintyre TA, Han C, Xiang H, Bambal R, Davis CB. Differences in the total body clearance of lead compounds in the rat and mouse: Impact on pharmacokinetic screening strategy. Xenobiotica 2008; 38: 605-619 (Pubitemid 351882974)
4. Hurst S, Loi CM, Brodfuehrer J, El-Kattan A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol 2007; 3:469-489 (Pubitemid 351324958)
5. Germani M, Crivori P, Rocchetti M, et al. Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Eur J Pharm Sci 2007; 31: 190-201. (Pubitemid 46830884)
6. Baranczewski P, Stanczak A, Sundberg K, et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 2006; 58: 453-462
7. Gombar VK, Silver IS, Zhao Z. Role of ADME characteristics in drug discovery and their in silico evaluation:in silico screening of chemicals for their metabolic stability. Curr Top Med Chem 2003; 3: 1205-1225
8. Caldwell J, Berova NM, McConnell O. Prologue: chirality in the pharmaceutical industry. Chirality 2007; 19: 657.
9. Elsby R, Surry DD, Smith VN, Gray AJ. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 2008; 38: 1140-1164
10. He G, Massarella J, Ward P. Clinical pharmacokinetics of the pro-drug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 471-484 (Pubitemid 30032251)
11. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor of oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000; 40: 836-843
12. Hill G, Cihlar T, Oo C, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 2002; 30: 13-19. (Pubitemid 34016935)
13. Snell P, Dave N, Wilson K, et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol 2005; 5: 598-601. (Pubitemid 40632252)
14. Abe M, Smith J, Urae A, Barrett J, Kinoshita H, Rayner CR. Pharmacokinetics of oseltamivir in young and very elderly Japanese subjects. Ann Pharmacol 2006; 40: 1724-1730 (Pubitemid 44544867)
15. Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 2007; 47: 689-696 (Pubitemid 46800424)
16. Gisclon LG, Boyd RA, Williams RL, Giacomini KM. The effect of probenecid on the renal elimination of cimetidine. Clin Pharmacol Ther 1989; 45: 444-452
17. Inotsume N, Nishimura M, Nakano M, Fujiyama S, Sato T. The inhibitory effect of probenecid on renal excretion of famotidine in youngm healthy volunteers. J Clin Pharmacol 1990; 30: 50-56 (Pubitemid 20072725)
18. Li S, Beringer PM, Hidayat L, et al. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. J Clin Pharmacol 2008; 48: 957-965 (Pubitemid 352009493)
19. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 1981; 6: 135-151
20. Wolf DL, Rodriguez CA, Mucci M, Ingrosso A, Duncan BA, Nickens DJ. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis, J Clin Pharmacol 2003; 43: 43-51. (Pubitemid 36015442)
21. Butler D. Wartime tactic doubles power of scarce bird-flu drug. Nature 2005; 4: 38-46
22. Holodniy M, Penzak SR, Straight TM, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008; 52: 3013-3021
23. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol 2008; 48: 935-947 (Pubitemid 352009487)
24. Moyle GJ, Youle M, Higgs C, et al. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a Phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol 1998; 38: 736-743 (Pubitemid 28388224)
25. Mascoline M. Nelfinavir is number 4 but should it bat cleanup, or lead off? J Int Assoc Physicians AIDS Care 1997; 3: 17-21.
26. Jackson KA, Rosenbaum SE, Kerr BM. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. Antimicrob Agents Chemother 2001; 45: 1086-1093
27. Khaliq Y, Gallicano K, Seguin I et al. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol 2000; 50: 108-115 (Pubitemid 30612028)
28. Damle B, Hewlett, D,Jr., Hsyu PH, Becker M, Petersen A. Pharmacokinetics of nelfinavir in subjects with hepatic impairment. J Clin Pharmacol 2006; 46: 1241-1249 (Pubitemid 44564353)
29. Zhang KE, Wu E, Patrick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001; 45: 1086-1093
30. Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metabol Dispos 2004; 32: 1462-1467
31. Yan JH, Marino MR, Smith RA, Kanamalauru V, O'Mara EM, Grasela DM. The effect of ravuconazole on the pharmacokinetics nelfinavir in healthy male volunteers. J Clin Pharmacol 2006; 46: 193-200. (Pubitemid 43146450)
32. Bergshoeff AS, Wolfs TF, Geelen SP, Burger DM. Ritonavirenhanced pharmacokinetics of nelfinavir/M8 during rifampicin use. Ann Pharmacother 2003; 37: 521-525
33. Piacenti FJ. An update and review of antiretroviral therapy. Pharmacother 2006; 26: 1111-1133
34. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008; 52: 1663-1669 (Pubitemid 351614658)
35. Srinivas NR. Unsuspected paradoxical drug interaction potential with rifampicin - Things to ponder with antiretroviral therapy. J Inf Dis 2009; 199: 766-767
36. Taxotere Prescribing Information - Sanofi Aventis. http://products. sanofi-aventis.us/Taxotere/taxotere.html.
37. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99-114.
38. Brunsvig PF, Andersen A, Aamdal S, Kristensen V, Olsen H. Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. BMC Cancer 2007; 7: 197-207.
39. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002; 62: 58-64. (Pubitemid 35244466)
40. Engels FK, Ten Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004; 75: 448-454 (Pubitemid 38534565)
41. Mallingre MM, Ten Bokkel Huinink WW, Mackay M, Schellens JH, Beijnen JH. Pharmacokinetics of oral cyclosporine A when co-administered to enhance the absorption of orally administered docetaxel. Eur J Clin Pharmacol 2001; 57: 305-307 (Pubitemid 32703937)
42. van Zuylen L, Sparreboom A, van deer Gaast A, et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101033. Eur J Cancer 2002; 38: 1090-1099 (Pubitemid 34468014)
43. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interaction with new psychotropic agents. Fundam Clin Pharmacol 2003; 17: 517-538 (Pubitemid 37215077)
44. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metabol 2002; 3: 13-27. (Pubitemid 34296308)
45. Srinivas NR. Clinical use of St. John's wort: drug-drug interaction potential of marketed products and challenges for drug development. Asian J Pharmacodyn Pharmacokinet 2008; 8: 109-126
46. Malingre MM, Beijnen JH, Rosing H, et al. The effect of different doses of cyclosporine A on the systemic exposure of orally administered paclitaxel. Anticancer Drugs 2001; 12: 351-358 (Pubitemid 32453441)
47. Meerum Terwogt JM, Malingre MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999; 5: 3379-3384
48. Chu Z, Chen JS, Liau CT, et al. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporine A in cancer patients. Anti Cancer Drugs 2008; 19: 275-281
49. Malingre MM, Schellens JH, Van Tellingen O, et al. The cosolvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 2001; 85: 1472-1477
50. Lau YY, Huang Y, Frassettro L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81: 194-204. (Pubitemid 46174816)
51. Oswald S, Giessmann T, Luetjohann D. Disposition and sterol-lowering effect of ezetemibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 2006; 80: 477-485 (Pubitemid 44767877)
52. Srinivas NR. The drug-drug interaction potential of rifampicin. Clin Ther 2008; 30: 1932-1933